Read more...

A recent study finds that Eliquis (apixaban), an oral factor Xa inhibitor drug, is very effective at reducing the risk of recurrent venous thromboembolism. The drug being developed by Pfizer and Bristol-Myers Squibb is an anticoagulant; it works by preventing the formation of blood clots in veins by inhibiting an enzyme in the coagulation cascade...